Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Merck Kgaa Dm 5 (MKGAF)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTHER OTC]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTHER OTC]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 13,557,277
  • Shares Outstanding, K 129,240
  • Annual Sales, $ 16,626 M
  • Annual Income, $ 1,803 M
  • 36-Month Beta 0.66
  • Price/Sales 0.84
  • Price/Cash Flow 2.67
  • Price/Book 0.88
  • Price/Earnings ttm 15.01
  • Earnings Per Share ttm 5.36
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 12/15/17
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
103.3900 +1.46%
on 11/10/17
107.5000 -2.42%
on 11/17/17
-1.8300 (-1.71%)
since 11/03/17
3-Month
103.3900 +1.46%
on 11/10/17
115.8000 -9.41%
on 09/26/17
-4.6000 (-4.20%)
since 08/31/17
52-Week
97.5600 +7.52%
on 12/08/16
124.4000 -15.68%
on 05/12/17
+5.1700 (+5.18%)
since 12/05/16

Most Recent Stories

More News
Pfizer/Merck KGaA's Bavencio Fails in Gastric Cancer Study

Pfizer & Merck KGaA's (MKGAF) Bavencio/avelumab fails in a phase III study evaluating it for the treatment of gastric cancer in the third-line setting.

JNJ : 143.12 (+1.40%)
HLUYY : 48.3100 (+0.68%)
PFE : 36.59 (+1.05%)
MKGAF : 106.8841 (+1.89%)
Orexigen (OREX) Q3 Loss Narrower Than Expected, Stock Up

Orexigen (OREX) reported a narrower-than-expected loss on higher Contrave volumes.

OREX : 1.34 (-2.90%)
SCMP : 16.45 (+1.23%)
TEVA : 16.52 (+0.49%)
MKGAF : 106.8841 (+1.89%)
Merck KGaA (MKGAF) Q3 Earnings Decline Y/Y, Revenues Flat

Merck KGaA (MKGAF) reported dismal third-quarter results with earnings declining year over year. Revenues were flat amid continued negative currency movement.

RHHBY : 30.3400 (+0.26%)
PFE : 36.59 (+1.05%)
MKGAF : 106.8841 (+1.89%)
BMY : 63.52 (+0.79%)
Merck KGaA (MKGAF) Q3 Earnings Down Y/Y, Sales Flat

Merck KGaA (MKGAF) reports a challenging third-quarter with earnings down year-over-year and sales remaining flat.

MKGAF : 106.8841 (+1.89%)
What's in the Cards for Merck KGaA (MKGAF) in Q3 Earnings?

Merck's (MKGAF) Healthcare and Life Science segments are expected to drive third-quarter sales. The company is progressing with its oncology drug, Bavencio and is also focusing on streamlining its business....

INO : 4.31 (-4.22%)
PFE : 36.59 (+1.05%)
MKGAF : 106.8841 (+1.89%)
PIRS : 5.86 (+0.69%)
Biogen & 6 Other Multiple Sclerosis Drug Stocks in Focus: Here's Why

Late last week, Biogen (BIIB) and six other pharma and biotech stocks were in the news due to the pricing of their multiple sclerosis ("MS") drugs.

BAYRY : 31.2900 (+0.58%)
NVS : 84.17 (+0.44%)
TEVA : 16.52 (+0.49%)
RHHBY : 30.3400 (+0.26%)
MKGAF : 106.8841 (+1.89%)
SNY : 43.95 (+0.57%)
BIIB : 325.74 (-0.70%)
Merck KGaA (MKGAF) Q2 Earnings Up Y/Y

Merck KGaA (MKGAF) reports second-quarter results with earnings rising year-over-year and sales registering organic growth.

MKGAF : 106.8841 (+1.89%)
What's in the Cards for Merck KGaA (MKGAF) in Q2 Earnings?

Merck KGaA???s (MKGAF) Life Science segment is expected to perform well following the approval of Bavencio.

ZTS : 72.31 (+0.75%)
CLVS : 62.47 (-0.68%)
PFE : 36.59 (+1.05%)
MKGAF : 106.8841 (+1.89%)
Merck KGaA (MKGAF) Q1 Earnings Fall Y/Y, Revenues Increase

Merck KGaA (MKGAF) reported first-quarter 2017 earnings of $1.28 per American Depositary Share, 14.7% lower than the year-ago figure of $1.50.

RHHBY : 30.3400 (+0.26%)
PFE : 36.59 (+1.05%)
MKGAF : 106.8841 (+1.89%)
BMY : 63.52 (+0.79%)
Merck KGaA (MKGAF) Q1 Earnings Down Y/Y, 2017 View Updated

The company???s first-quarter 2017 earnings per American Depositary Receipt (ADR) came in at $1.28, compared to the year-ago figure of $1.50

MKGAF : 106.8841 (+1.89%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

See More

Key Turning Points

2nd Resistance Point 105.8100
1st Resistance Point 105.3550
Last Price 106.8841
1st Support Level 104.6600
2nd Support Level 104.4200

See More

52-Week High 124.4000
Fibonacci 61.8% 114.1471
Fibonacci 50% 110.9800
Fibonacci 38.2% 107.8129
Last Price 106.8841
52-Week Low 97.5600

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.